Curadel Pharma

Curadel Pharma is a clinical-stage biopharmaceutical company focused on developing radiopharmaceuticals and imaging agents to improve cancer treatment and surgery. The company was founded in 2012 by Dr. John V. Frangioni, an oncologist and former professor at Harvard Medical School, to translate academic research into commercial products. Dr. Frangioni, who holds an M.D. from Harvard Medical School and a Ph.D. in Cellular & Molecular Physiology from Harvard University, has dedicated nearly 30 years to the field of cancer imaging and treatment, particularly in reducing background noise to enhance visibility. After two decades in academia, he established Curadel to move his technologies into the clinical setting where they could directly benefit patients.

The company's core technology revolves around zwitterionic chemistry, a concept that creates a net-zero-charged forcefield around a drug's core. This property prevents the drug from binding non-specifically to healthy tissues, allowing for rapid clearance through the kidneys while precisely targeting cancer cells. This approach aims to deliver a powerful therapeutic payload to tumors, minimizing collateral damage and overcoming tumor resistance, a major cause of treatment failure. Curadel Pharma's business model involves in-house research and development, funded through a combination of grants, including over $60 million from the NIH and other agencies to its founder, and venture capital, such as a $10.5M Series A2 round to advance its lead programs. The company serves the oncology and surgical markets by developing drugs for both therapeutic and diagnostic applications, and it actively seeks corporate partnerships.

Curadel's product pipeline features two main platforms. The first is its therapeutic Audacious Alpha™ platform, which leverages zwitterionic technology for targeted alpha therapies (TATs). Its lead therapeutic candidate, CPI-003, is designed to eradicate tumors completely, preventing the regrowth often seen with other treatments. The second platform is for optical surgical navigation, using near-infrared (NIR) fluorescence. A key product in this area is ZW800-1 (nizaracianine triflutate), an investigational imaging agent currently in a global Phase 3 trial. When used with an NIR camera system, ZW800-1 makes the ureters visible during surgery in real-time, helping surgeons avoid accidental injury during abdominal and pelvic procedures. This technology, part of the FLARE® (Fluorescence-Assisted Resection and Exploration) portfolio, was originally developed by Dr. Frangioni and is designed to empower surgeons by making otherwise invisible anatomical structures visible.

Keywords: targeted alpha therapy, radiopharmaceuticals, zwitterionic drugs, near-infrared imaging, surgical navigation, oncology, cancer treatment, metastatic cancer, image-guided surgery, ZW800-1, FLARE technology, John Frangioni, medical imaging, biopharmaceutical, cancer research, drug development, clinical trials, optical imaging, pan-tumor platform, tumor resistance